SBIR/STTR Research Award
METHOD FOR INCREASING GENE THERAPY EFFICACY AND SAFETY
Award amount
$100,000Program and phase
SBIR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOTRANSPLANT, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by the applicant): The aim of this proposal is to develop
a non-myeloablative conditioning protocol with increased safety and efficacy
for the induction of specific immune tolerance to genetically modified cells.
Potential applications of gene therapy in the treatment of genetic and
autoimmune disorders are widespread, but progress has suffered from a severe
reduction in efficacy due to immune reactions raised against therapeutic
transgene products. Induction of specific immune tolerance through mixed
hematopoietic chimerism is an established methodology that can effectively
re-educate the immune system to eliminate immune rejection. To achieve
engraftment of allogeneic stem cells, conditioning requirements are associated
with toxicities, and graft-versus-host disease is a common side effect. Studies
have shown that molecular chimerism can be used to induce tolerance. Our
preliminary data suggest that specific immune tolerance can be induced to a
single immunogenic protein expressed on autologous cells, and that conditioning
requirements for transplantation of molecularly modified autologous cells are
less than those required for allogeneic transplants. We believe that the
effectiveness of gene therapy can be greatly improved by inducing specific
immune tolerance to foreign proteins to be transferred and that this can be
accomplished using non-toxic protocols.
Technology keywords
Not reported